Amna Ibrahim

6.4k total citations · 1 hit paper
58 papers, 2.9k citations indexed

About

Amna Ibrahim is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, Amna Ibrahim has authored 58 papers receiving a total of 2.9k indexed citations (citations by other indexed papers that have themselves been cited), including 27 papers in Oncology, 23 papers in Pulmonary and Respiratory Medicine and 20 papers in Cancer Research. Recurrent topics in Amna Ibrahim's work include Cancer Treatment and Pharmacology (11 papers), Cancer Genomics and Diagnostics (10 papers) and HER2/EGFR in Cancer Research (9 papers). Amna Ibrahim is often cited by papers focused on Cancer Treatment and Pharmacology (11 papers), Cancer Genomics and Diagnostics (10 papers) and HER2/EGFR in Cancer Research (9 papers). Amna Ibrahim collaborates with scholars based in United States, Egypt and Sudan. Amna Ibrahim's co-authors include Richard Pazdur, Rajeshwari Sridhara, Shenghui Tang, Robert Justice, Julia A. Beaver, Martin H. Cohen, Kirsten B. Goldberg, V. Ellen Maher, Laleh Amiri‐Kordestani and Paul G. Kluetz and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and The Lancet Oncology.

In The Last Decade

Amna Ibrahim

55 papers receiving 2.9k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

FDA Approval Summary: Lutetium Lu 177 Vipivotide Tetraxetan for Patients with Metastatic Castration-Resistant Prostate Cancer

2022 127 citations Jaleh Fallah, Sundeep Agrawal et al. Clinical Cancer Research profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Amna Ibrahim United States	26	1.7k	1.1k	744	615	457	58	2.9k
Laleh Amiri‐Kordestani United States	28	1.9k 1.1×	1.0k 0.9×	713 1.0×	497 0.8×	558 1.2×	89	3.1k
Paula M. Fracasso United States	31	1.6k 1.0×	477 0.4×	1.0k 1.4×	407 0.7×	380 0.8×	109	3.0k
Scott N. Holden United States	23	2.2k 1.3×	860 0.8×	1.3k 1.8×	823 1.3×	424 0.9×	44	3.7k
Susan Galbraith United States	23	1.1k 0.6×	523 0.5×	957 1.3×	696 1.1×	610 1.3×	45	2.9k
Paolo Tarantino Italy	28	2.3k 1.3×	826 0.8×	632 0.8×	1000 1.6×	777 1.7×	128	3.2k
Zefei Jiang China	30	2.5k 1.5×	1.2k 1.1×	1.1k 1.5×	744 1.2×	915 2.0×	198	3.8k
Binghe Xu China	26	2.4k 1.4×	1.0k 0.9×	666 0.9×	482 0.8×	1000 2.2×	149	3.1k
Richard A. Messmann United States	21	1.2k 0.7×	1.4k 1.3×	976 1.3×	1.3k 2.2×	362 0.8×	49	3.2k
Shunchang Jiao China	30	1.9k 1.1×	977 0.9×	1.1k 1.5×	389 0.6×	655 1.4×	144	3.4k
Neville Davidson United Kingdom	14	3.7k 2.2×	1.2k 1.1×	1.3k 1.7×	883 1.4×	793 1.7×	25	5.0k

Countries citing papers authored by Amna Ibrahim

Since Specialization

Citations

This map shows the geographic impact of Amna Ibrahim's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Amna Ibrahim with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Amna Ibrahim more than expected).

Fields of papers citing papers by Amna Ibrahim

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Amna Ibrahim. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Amna Ibrahim. The network helps show where Amna Ibrahim may publish in the future.

Co-authorship network of co-authors of Amna Ibrahim

This figure shows the co-authorship network connecting the top 25 collaborators of Amna Ibrahim. A scholar is included among the top collaborators of Amna Ibrahim based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Amna Ibrahim. Amna Ibrahim is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Ibrahim, Amna, et al.. (2025). Breaking Barriers in Huntington’s Disease Therapy: Focused Ultrasound for Targeted Drug Delivery. Neurochemical Research. 50(1). 68–68. 2 indexed citations

Ibrahim, Amna, et al.. (2025). Conventional vs. device-assisted paediatric circumcision: A systematic review and meta-analysis. Journal of Pediatric Urology. 21(5). 1209–1218.

Ahmad, Owais, Santosh Rath, Bhavya Sharma, et al.. (2025). Safety and efficacy of pemigatinib in patients with cholangiocarcinoma: a systematic review. Journal of Gastrointestinal Oncology. 16(2). 699–710. 1 indexed citations

Bacon, Andrew, Amna Ibrahim, Penelope Smyth, et al.. (2024). A cohort study examining predictors of stroke and bleeding among people with congenital heart disease and atrial fibrillation. European Heart Journal. 45(Supplement_1). 1 indexed citations

Magdy, Rehab, et al.. (2023). Validation of the Arabic version of Parkinson's Disease Sleep Scale-Revised Version (PDSS-2). Revue Neurologique. 180(3). 195–201. 2 indexed citations

Ibrahim, Amna, et al.. (2023). Retinal functional and structural changes in patients with Parkinson’s disease. BMC Neurology. 23(1). 330–330. 9 indexed citations

Lee, Daniel, Haley Gittleman, Chana Weinstock, et al.. (2023). A U.S. Food and Drug Administration–pooled Analysis of Frontline Combination Treatment Survival Benefits by Risk Groups in Metastatic Renal Cell Carcinoma. European Urology. 84(4). 373–378. 8 indexed citations

Fallah, Jaleh, Sundeep Agrawal, Haley Gittleman, et al.. (2022). FDA Approval Summary: Lutetium Lu 177 Vipivotide Tetraxetan for Patients with Metastatic Castration-Resistant Prostate Cancer. Clinical Cancer Research. 29(9). 1651–1657. 127 indexed citations breakdown →

Brave, Michael H., Chana Weinstock, Jamie R. Brewer, et al.. (2020). An FDA Review of Drug Development in Nonmetastatic Castration-resistant Prostate Cancer. Clinical Cancer Research. 26(18). 4717–4722. 20 indexed citations

10.

Wedam, Suparna, Lola A. Fashoyin‐Aje, Xin Gao, et al.. (2020). FDA Approval Summary: Ado-Trastuzumab Emtansine for the Adjuvant Treatment of HER2-positive Early Breast Cancer. Clinical Cancer Research. 26(16). 4180–4185. 65 indexed citations

11.

Amiri‐Kordestani, Laleh, Diqiong Xie, Sara M. Tolaney, et al.. (2020). A Food and Drug Administration analysis of survival outcomes comparing the Adjuvant Paclitaxel and Trastuzumab trial with an external control from historical clinical trials. Annals of Oncology. 31(12). 1704–1708. 15 indexed citations

12.

Gao, Jennifer, Joyce Cheng, Erik Bloomquist, et al.. (2019). CDK4/6 inhibitor treatment for patients with hormone receptor-positive, HER2-negative, advanced or metastatic breast cancer: a US Food and Drug Administration pooled analysis. The Lancet Oncology. 21(2). 250–260. 194 indexed citations

13.

Suzman, Daniel L., Sundeep Agrawal, V. Ellen Maher, et al.. (2018). FDA Approval Summary: Atezolizumab or Pembrolizumab for the Treatment of Patients with Advanced Urothelial Carcinoma Ineligible for Cisplatin-Containing Chemotherapy. The Oncologist. 24(4). 563–569. 138 indexed citations

14.

Howie, Lynn, Nancy S. Scher, Laleh Amiri‐Kordestani, et al.. (2018). FDA Approval Summary: Pertuzumab for Adjuvant Treatment of HER2-Positive Early Breast Cancer. Clinical Cancer Research. 25(10). 2949–2955. 50 indexed citations

15.

Shah, Anand, Erik Bloomquist, Shenghui Tang, et al.. (2018). FDA Approval: Ribociclib for the Treatment of Postmenopausal Women with Hormone Receptor–Positive, HER2-Negative Advanced or Metastatic Breast Cancer. Clinical Cancer Research. 24(13). 2999–3004. 88 indexed citations

16.

Jarow, Jonathan P., V. Ellen Maher, Shenghui Tang, et al.. (2015). Development of Systemic and Topical Drugs to Treat Non-muscle Invasive Bladder Cancer. Bladder Cancer. 1(2). 133–136. 13 indexed citations

17.

Ning, Yang‐Min, Michael H. Brave, V. Ellen Maher, et al.. (2015). U.S. Food and Drug Administration Approval Summary: Enzalutamide for the Treatment of Patients With Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer. The Oncologist. 20(8). 960–966. 35 indexed citations

18.

Ryan, Qin, Amna Ibrahim, Martin H. Cohen, et al.. (2008). FDA Drug Approval Summary: Lapatinib in Combination with Capecitabine for Previously Treated Metastatic Breast Cancer That Overexpresses HER-2. The Oncologist. 13(10). 1114–1119. 236 indexed citations

19.

Ibrahim, Amna, Nancy S. Scher, Grant Williams, et al.. (2003). Approval summary for zoledronic acid for treatment of multiple myeloma and cancer bone metastases.. PubMed. 9(7). 2394–9. 157 indexed citations

20.

Ibrahim, Amna, et al.. (1969). Effect of a New Low-Dosage Oral Contraceptive Pill on Blood Electrolytes. Fertility and Sterility. 20(3). 405–413. 4 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact